The Melanoma Market and Implications of Key Data From SITC 2023
Duration: 60 minutes The 2023 Society for Immunotherapy of Cancer (SITC) annual conference will feature some key catalysts for the melanoma market. Join Bloomberg Intelligence analysts Max Nisen and Tish Walker as they discuss the latest development in the melanoma market, including the rise of neoadjuvant therapy as a potential new standard of care. We'll also discuss the potential size of that market and the upcoming patent cliff for melanoma mainstays like Opdivo and Keytruda and the possibility for the Inflation Reduction Act to cut prices first.
Speakers
Max Nisen
Analyst
Bloomberg Intelligence
Max Nisen is a senior associate equity research analyst specializing in the pharmaceutical and biotechnology sector. Prior to joining Bloomberg Intelligence, Max was the founding health care columnist for Bloomberg Gadfly and later Bloomberg Opinion, where he wrote about the pharmaceutical industry, managed care, policy and public health. Before that, he covered business and financial news at Quartz and Business Insider. Max earned a bachelor’s degree in economics from Pomona College.
Tish Walker
Senior Research Analyst
Bloomberg Intelligence
Letitia (Tish) Walker is a Senior Litigation Analyst on the healthcare team at Bloomberg Intelligence. Prior to Bloomberg, Tish was a Director in the intellectual property group at Merck & Co, Inc. where she was responsible patent procurement, freedom to operate analysis, and due diligence for large molecule products and pipeline programs. Before joining Merck, she was a Partner at Akerman LLP, where her practice primarily focused on patent opinion work for companies seeking to enter the market with a biosimilar or generic product. Tish began her law career at a boutique firm in NYC where her focus was on drafting and procuring life science related patents in various regions. Tish holds a law degree from Brooklyn Law School, a Master’s in Biology from New York University, and a Bachelor’s degree in Chemistry from The George Washington University.
Dr. Richard Wu
Medical Oncologist and Assistant Professor of Medicine
Ohio State University Comprehensive Cancer Center
Dr. Richard Wu, PhD, is a Medical Oncologist and an Assistant Professor of Medicine at the Ohio State University Comprehensive Cancer Center (08/2020-present). He specializes in treating patients with melanoma and non-melanoma skin cancer (i.e., melanoma, carcinoma). His clinical expertise is in skin cancers, cutaneous, medical oncology, melanoma, carcinoma (basal cell), carcinoma (Merkel cell), immunotherapy, and carcinoma (squamous cell). As an Assistant Professor of Medicine, Dr. Wu specializes in cutaneous medical oncology with a focus on melanoma and early-phase drug development. He also performs immunotherapy research on melanoma that has been published in prestigious journals, and his findings have been presented at international and national medical conferences. A board-certified medical oncologist, Dr. Wu received his MD and PhD degrees from the University of Texas McGovern Medical School at the Houston/MD Anderson Cancer Center as part of the NIH-funded Medical Scientist Training Program.